Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • •Wiek co najmniej 18 lat
  • •Potwierdzony histologicznie neuroendokrynny nowotwór (stopnie 1-3) rozprzestrzeniający się lub nieoperacyjny
  • •Nowotwór z obszaru żołądka, jelit lub trzustki (grupa A)
  • •Inne nowotwory o receptorach somatostatyny - płuco, tarczyca, pierś, narządy płciowe, nadnercze lub oponiak (grupa B)
  • •Potwierdzenie receptorów somatostatyny badaniem obrazowym PET
  • •Prawidłowa funkcja nerek, wątroby i morfologia krwi

✗ Disqualifies

  • •Wcześniejsze leczenie radioaktywnymi peptydami (Lu-177 lub inne)
  • •Wcześniejszy przeszczep narządu lub szpiku
  • •Przewlekłe stosowanie sterydów
  • •Poważne choroby serca
  • •Oporna na leczenie nadciśnienie tętnicze
  • •Niekontrolowana cukrzyca
  • •Historia marskości wątroby
  • •Infekcja HIV, zapalenie wątroby typu B lub C

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
September 15, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (14)

Research Facility

Phoenix, United States

Research Facility

Jacksonville, United States

Research Facility

Iowa City, United States

Research Facility

Lexington, United States

Research Facility

Rochester, United States

Research Facility

St Louis, United States

Research Facility

St Louis, United States

Research Facility

Columbus, United States

Research Facility

Portland, United States

Research Facility

Nashville, United States

Research Facility

Salt Lake City, United States

Research Facility

Charlottesville, United States

Research Facility

Toronto, Canada

Research Facility

Montreal, Canada

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/16/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.